Cargando…
Recombinant Human PH20: Baseline Analysis of the Reactive Antibody Prevalence in the General Population Using Healthy Subjects
BACKGROUND: Recombinant human PH20 (rHuPH20) is used to depolymerize hyaluronan in the subcutaneous space, increasing the dispersion and absorption of co-administered drugs. While ~ 5 to 10% of rHuPH20 treatment-naïve healthy volunteers have demonstrated rHuPH20-reactive antibodies, associations wit...
Autores principales: | Rosengren, Sanna, Souratha, Jennifer, Conway, Dave, Muchmore, Douglas B., Sugarman, Barry J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814530/ https://www.ncbi.nlm.nih.gov/pubmed/29442293 http://dx.doi.org/10.1007/s40259-018-0260-y |
Ejemplares similares
-
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers
por: Printz, Marie A., et al.
Publicado: (2020) -
Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration
por: Rosengren, Sanna, et al.
Publicado: (2015) -
Dispersive effects and focused biodistribution of recombinant human hyaluronidase PH20: A locally acting and transiently active permeation enhancer
por: Kang, David W., et al.
Publicado: (2021) -
PH20 is not expressed in murine CNS and oligodendrocyte precursor cells
por: Marella, Mathieu, et al.
Publicado: (2017) -
Propofol pharmacokinetics in young healthy Indian subjects
por: Puri, Avinash, et al.
Publicado: (2012)